{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:03:03Z","timestamp":1783350183220,"version":"3.54.6"},"reference-count":31,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019573","name":"Amsterdam University Medical Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,8,15]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Aneurysmal subarachnoid haemorrhage (aSAH) is a severe condition associated with significant morbidity and case fatality rate. Delayed cerebral ischaemia (DCI) is a major factor contributing to poor outcomes. For long, DCI was thought to be caused by vasospasm, induced by blood in the subarachnoid space. Growing experimental and clinical evidence has shown an activation of the coagulation cascade and several other (intravascular) pathophysiological pathways, affecting the cerebral microcirculation. In a retrospective analysis of our aSAH patient registry, we observed lower in-hospital mortality and a significantly higher rate of discharge-to-home in patients treated with high-dose nadroparin, compared with patients treated with low-dose (prophylactic) nadroparin. This observation suggests a potential benefit of higher doses of nadroparin in the acute course after aSAH. We therefore hypothesise that treatment with high-dose nadroparin will improve clinical outcome in endovascularly treated patients with aSAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a single-centre, prospective, phase II randomised controlled trial. From January 2022, all eligible patients will be recruited. 100 patients will be randomised to the intervention arm, that is, nadroparin two times per day 5700 AxaIU, or the control arm, that is, nadroparin once daily 2850 AxaIU in patients with body weight \u2264100\u2009kg or once daily 5700 AxaIU in patients with body weight &gt;100\u2009kg, both for up to 21 days. The trial includes a 6-month follow-up period. The primary objective is 30-day mortality rate. Secondary outcomes include assessment of DCI, complications during admission, discharge location, clinical outcome (modified Rankin Scale), quality of life and total healthcare costs at 3 and 6 months follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Approval was obtained from the Medical Research Ethics Committee of the Amsterdam UMC, location Academic Medical Center (AMC) (MREC-number 2020_192), and recruitment has begun. The study results will be submitted for publication in peer-reviewed journals and presented at international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04507178\">NCT04507178<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-096555","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:35:30Z","timestamp":1756406130000},"page":"e096555","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Improving outcome in SubaraChnoid HEMorrhage wIth nAdroparin (ISCHEMIA): a prospective randomised controlled trial protocol"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04507178","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04507178","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-8707","authenticated-orcid":false,"given":"Nadine","family":"Denneman","sequence":"first","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom C","family":"Doorschodt","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, OLVG, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert A","family":"Coert","sequence":"additional","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"van den Berg","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B L M","family":"Majoie","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella C A","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Coppens","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus A","family":"Kempeneers","sequence":"additional","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud A","family":"Tjerkstra","sequence":"additional","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homeyra","family":"Labib","sequence":"additional","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harssh Verdan","family":"Bandral","sequence":"additional","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Baarse","sequence":"additional","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa E","family":"Platek","sequence":"additional","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Peter","family":"Vandertop","sequence":"additional","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Verbaan","sequence":"additional","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Post","sequence":"additional","affiliation":[{"name":"Neurosurgical Center Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"},{"name":"Neurovascular Disorders, Amsterdam Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"2025123106480689000_15.8.e096555.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70126-7"},{"key":"2025123106480689000_15.8.e096555.2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1212\/WNL.50.5.1413","article-title":"The burden, trends, and demographics of mortality from subarachnoid hemorrhage","volume":"50","author":"Johnston","year":"1998","journal-title":"Neurology (ECronicon)"},{"key":"2025123106480689000_15.8.e096555.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.3.337"},{"key":"2025123106480689000_15.8.e096555.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60975-2"},{"key":"2025123106480689000_15.8.e096555.5","article-title":"Calcium antagonists for aneurysmal subarachnoid haemorrhage","volume":"2005","author":"Rinkel","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2025123106480689000_15.8.e096555.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307711"},{"key":"2025123106480689000_15.8.e096555.7","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2008.74"},{"key":"2025123106480689000_15.8.e096555.8","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22050724","article-title":"Heparin and Heparin-Derivatives in Post-Subarachnoid Hemorrhage Brain Injury: A Multimodal Therapy for a Multimodal Disease","volume":"22","author":"Hayman","year":"2017","journal-title":"Molecules"},{"key":"2025123106480689000_15.8.e096555.9","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aes264"},{"key":"2025123106480689000_15.8.e096555.10","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-198112000-00012"},{"key":"2025123106480689000_15.8.e096555.11","doi-asserted-by":"publisher","DOI":"10.1016\/0090-3019(82)90011-8"},{"key":"2025123106480689000_15.8.e096555.12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1161\/01.STR.18.6.1169","article-title":"Is there a role for heparin in the management of complications of subarachnoid hemorrhage?","volume":"18","author":"Chimowitz","year":"1987","journal-title":"Stroke"},{"key":"2025123106480689000_15.8.e096555.13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1227\/00006123-199203000-00005","article-title":"Accelerated nonmuscle contraction after subarachnoid hemorrhage: culture and characterization of myofibroblasts from human cerebral arteries in vasospasm","volume":"30","author":"Yamamoto","year":"1992","journal-title":"Neurosurgery"},{"key":"2025123106480689000_15.8.e096555.14","doi-asserted-by":"publisher","DOI":"10.1007\/BF01808557"},{"key":"2025123106480689000_15.8.e096555.15","doi-asserted-by":"crossref","DOI":"10.3171\/2021.12.FOCUS21419","article-title":"Heparin in the treatment of aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis","volume":"52","author":"Lukito","year":"2022","journal-title":"Neurosurg Focus"},{"key":"2025123106480689000_15.8.e096555.16","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.32.4.993"},{"key":"2025123106480689000_15.8.e096555.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2002.tb00213.x"},{"key":"2025123106480689000_15.8.e096555.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2010.00845.x"},{"key":"2025123106480689000_15.8.e096555.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12975-012-0166-9"},{"key":"2025123106480689000_15.8.e096555.20","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-010-9435-1"},{"key":"2025123106480689000_15.8.e096555.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.10.026"},{"key":"2025123106480689000_15.8.e096555.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.05959.x"},{"key":"2025123106480689000_15.8.e096555.23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.carbpol.2016.12.037","article-title":"Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review","volume":"160","author":"Yan","year":"2017","journal-title":"Carbohydr Polym"},{"key":"2025123106480689000_15.8.e096555.24","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2016-012925"},{"key":"2025123106480689000_15.8.e096555.25","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyx381"},{"key":"2025123106480689000_15.8.e096555.26","first-page":"305","article-title":"Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin","volume":"72","author":"van Roessel","year":"2014","journal-title":"Neth J Med"},{"key":"2025123106480689000_15.8.e096555.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.03.023"},{"key":"2025123106480689000_15.8.e096555.28","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1055\/s-0037-1614988","article-title":"Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose","volume":"79","author":"Boneu","year":"1998","journal-title":"Thromb Haemost"},{"key":"2025123106480689000_15.8.e096555.29","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.32.6.1310"},{"key":"2025123106480689000_15.8.e096555.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"2025123106480689000_15.8.e096555.31","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-020-01093-w","article-title":"Optimal designs for phase II\/III drug development programs including methods for discounting of phase II results","volume":"20","author":"Erdmann","year":"2020","journal-title":"BMC Med Res Methodol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-096555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:50:45Z","timestamp":1767192645000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-096555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,28]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2024-096555"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-096555","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}